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Abstract 3 
Objective: Although alcohol is a leading risk factor for osteonecrosis of the femoral head (ONFH) and 4 
its prevalence reportedly ranges from 20% to 45%, there are no unified classification criteria for this sub-5 
population. In 2015, Association Research Circulation Osseous (ARCO) decided to develop classification 6 
criteria for alcohol-associated ONFH (AA-ONFH). 7 
Methods: In June of 2017, ARCO formed a task force to conduct a Delphi survey. The task force invited 8 
twenty-eight experts in osteonecrosis/bone circulation from eight countries. Each round of the Delphi 9 
survey included questionnaires, analysis of replies, and feedback reports to the panel. After three rounds 10 
of the survey, consensus was reached on the classification criteria. The response rates for the three Delphi 11 
rounds were 100% (Round 1), 96% (Round 2), and 100% (Round 3). 12 
Results: The consensus on the classification criteria of AA-ONFH included: 1) patients should have a 13 
history of alcohol intake > 400 mL/week (320 g/week, any type of alcoholic beverage) of pure ethanol for 14 
more than 6 months; 2) ONFH should be diagnosed within 1 year after alcohol intake of this dose; and 3) 15 
patients should not have other risk factor(s).  16 
Conclusion: ARCO established classification criteria to standardize clinical studies concerning AA-17 
ONFH.  18 
Key words: osteonecrosis; avascular necrosis; hip; femoral head; alcohol; Delphi 19 
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Introduction 21 
 Since 1922, when the association between osteonecrosis of the femoral head (ONFH) and alcohol abuse 22 
was first presented,[1] alcohol consumption has been known as an important risk factor for non-traumatic 23 
osteonecrosis of the femoral head (ONFH). [2-4] Epidemiologic studies previously reported that 20% to 24 
45% of ONFH patients were associated with alcohol overuse.[5-10] However, individual susceptibility 25 
for the development of alcohol-associated ONFH (AA-ONFH) varies widely and depends not only on the 26 
extent of exposure to ethanol, but also to genetic predispositions[11-14] although a statistical significant 27 
dose-response relationship was shown in a recent meta-analysis.[15] HIrota et al. reported that, when 28 
compared to non-drinker, the odds ratio tended to be increased even in low-risk drinkers; 2.8 [95% 29 
confidence interval (CI), 1.0-7.8] in subjects with weekly ethanol intake < 320 g or 2.2 [95% CI, 0.7-6.9] 30 
in subjects with < 3200 (g/week per year).[16] On the contrary, the incidence of osteonecrosis was 31 
reported to be only 0.3 to 5% in patients with chronic alcoholism. Therefore, it is difficult to practically 32 
determine a unifying cut-off dose of alcohol to develop AA-ONFH.[17, 18] 33 
 On this context, the definition or classification criteria varies widely across previous studies on AA-34 
ONFH. Among 18 English-written studies published from 2015 to 2017 with a sample size of 200 or 35 
more, 6 studies used 400 mL/week as the cut-off level of alcohol exposure,[19-24] 2 studies did 900 36 
mL/week,[25, 26] and one study did 40 g/day for men or 20 g/day for women to defined AA-ONFH.[3] 37 
Even a worse problem is that 50% (9/18) did not describe their definition for AA-ONFH.[4, 9, 10, 24, 27-38 
31] Such heterogeneity is an important obstacle for collaborative efforts to study AA-ONFH and makes it 39 
difficult to compare the results across the studies or to collect data enough to augment our understanding 40 
of AA-ONFH. 41 
 In April 2015, Association Research Circulation Osseous (ARCO) addressed some of these issues on 42 
classification criteria of non-traumatic ONFH and formed a task force to establishing the criteria for AA-43 
ONFH and glucocorticoid-associated osteonecrosis (GA-ONFH), and conducted a Delphi survey to 44 
establish classification issues. 45 
 The criteria of GA-ONFH were described elsewhere as a Part 1 study,[blinded by authors] and this is the 46 
Part 2 study concerning the criteria for AA-ONFH. 47 
Methods 48 
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Participants 49 
The ARCO task force was set up to prepare the Delphi survey and consisted of 7 members; 4 50 
orthopaedic surgeons, 1 expert researcher on bone circulation/osteonecrosis, 1 rheumatologist and 1 51 
statistician/methodologist. The task force performed a search of PubMed, using the key search terms 52 
“osteonecrosis”, “avascular necrosis”, “aseptic necrosis”, and “alcohol” for entries from January 1, 1960, 53 
to May 31, 2017. A total of 50 reports on AA-ONFH were identified and reviewed. The task force 54 
selected 6 key studies which investigated the risk of ONFH and alcohol intake including cross-sectional, 55 
case-control and cohort studies (Supplementary 1). Through the comprehensive literature review, the task 56 
force raised 4 issues to develop novel etiologic classification criteria of AA-ONFH; 1) whether panelists 57 
necessitated classification criteria for AA-ONFH; 2) the minimal dose of alcohol intake; 3) the latent 58 
period after alcohol intake of such dose, when a diagnosis of ONFH should be made; and 4) how to 59 
classify ONFH patients who have other risk factor(s) than alcohol. 60 
In June of 2017, the task force initially invited 30 experts and ARCO made the panel qualifications for 61 
the Delphi study; college faculty, more than 10 years of clinical and/or research experience, and 3 or more 62 
publications on bone circulation/osteonecrosis. Among the 30 experts, one declined the invitation and one 63 
did not reply to the invitation. The remaining 28 experts on osteonecrosis/bone circulation participated in 64 
the Delphi procedure. The panel members had a mean of approximately 18 years of clinical and/or 65 
research experience. 66 
The modified Delphi procedure 67 
 The modified Delphi technique is a means of reaching a group consensus through multiple rounds of 68 
anonymous feedback and iterations and, especially, is valuable in situations where imprecise or 69 
contradictory opinions exist.[32] The details of our Delphi method are referred to the Part 1: 70 
glucocorticoid-associated osteonecrosis. Briefly, in the first round, the panel members were asked to 71 
answer 4 open-ended questions on the above-mentioned issues. In the second and further rounds, the 72 
panel members were asked to answer the revised questionnaires on the issues, on which consensus was 73 
not reached in the previous round. Between survey rounds, the response summary of the previous round 74 
was presented as anonymous feedback. In our study, 3 rounds were employed until final consensus was 75 
obtained on the 4 issues of AA-ONFH. A consensus was determined based on a content validity ratio 76 
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(CVR) of 0.357 or greater which means that 19 is a minimum number required to reach a consensus in 77 
each questionnaire among 28 panels.[33] 78 
Source of Funding 79 
No external funding was received in support of this work and ARCO. 80 
Results 81 
Through three consecutive Delphi rounds, full consensus was reached on the classification criteria of AA-82 
ONFH. 83 
Round 1: Open round 84 
Four questionnaires were sent to the panel members, and the response rate was 100% in Round 1. 85 
 From the replies to the first Delphi survey, consensus was reached on one issue (question 1) about the 86 
necessity for the classification criteria. Twenty-three panel members (82.1%) agreed with the necessity 87 
for the classification criteria, whereas five members (17.9%) disagreed. The most common reason for the 88 
agreement was that although alcohol is a leading risk factor of non-traumatic ONFH, there are no defined 89 
classification criteria.  90 
 Consensus was not reached on the remaining four issues; minimal dose of alcohol consumption, 91 
duration of alcohol consumption, latent period, as well as how to classify patients with multiple risk 92 
factors (Table 1). Several panel members also suggested changing the term “alcohol-induced” to “alcohol 93 
-associated” because the exact causal relationship between alcohol intake and the development of ONFH 94 
has yet to be determined. 95 
Round 2: Selecting and limiting round with multiple choice questions 96 
 Questionnaires on the three issues, on which consensus was not reached in Round 1, were modified to 97 
multiple-choice questions in order to attempt convergence of the various replies. Five multiple-choice 98 
questionnaires were made using lists of categories and panelists were asked to select the most appropriate 99 
category. The issue of terminology change from “alcohol-induced” to “alcohol-associated” was also 100 
included in Round 2. 101 
 The response rate was 96% in Round 2. Consensus was reached on three issues: the minimum dose of 102 
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alcohol consumption; classification of patients with multiple risk factors; and the term issue. However, 103 
consensus was not reached on the two issues of the duration of alcohol consumption and the latent period 104 
(Table 2). 105 
Round 3: Ranking round  106 
To attempt convergence on the two issues unresolved in Round 2, the panel members were given the 107 
opportunity to state whether or not they agreed with the category showing the highest response frequency 108 
in Round 2 and to re-enter their rationale or reason why they did not agree. This was to ensure that the 109 
respondents had the opportunity to state whether or not they agreed with the category showing the highest 110 
response frequency in Round 2. The response rate was 100% in Round 3. As consensus was reached on 111 
the remaining two queries, the classification criteria for AA-ONFH was made (Table 3). 112 
Final consensus 113 
To classify an ONFH patient as an AA-ONFH patient: 1) they should have a history of mean alcohol 114 
consumption > 400 mL/week (320 g/week, any type of alcoholic beverage) for more than 6 months; 2) 115 
ONFHs should be diagnosed within one year after alcohol intake of such dose; and 3) the patient should 116 
not have other risk factor(s) than excessive alcohol intake (Table 4). 117 
Approval of the consensus 118 
The final consensus on the classification criteria of AA-ONFH was approved in the general meeting of 119 
ARCO, which was held in October 25, 2017 in Berlin 120 
Discussion 121 
 In 1988, the influence of alcohol on the development of ONFH was first reported in a multicenter case-122 
control study.[34] However, although previous studies showed that current consumption and cumulative 123 
amount were positively associated with non-traumatic ONFH, many researchers have used their own 124 
criteria for classification or definition. The proportion of AA-ONFH has been variously reported in 125 
studies of non-traumatic ONFH. In a systematic review of 67 reports on total hip arthropathy (including 126 
14 Asian studies), 19% had excessive alcohol consumption as an etiologic factor among in 2,593 patients 127 
with ONFH.[35] However, in some epidemiological studies with large sample size (N > 150) published 128 
during the recent 20 years, the prevalence of AA-ONFH was from 20% to 45%; 36.7% in USA[5], 32.4% 129 
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in Korea 31.8%[7], in China[9], 45.2% in Taiwan[10], 31% in Japan[8], and 20.1% in India.[36] 130 
Moreover, the frequencies of AA-ONFH in clinical studies having small sample size much more varied 131 
across the studies (from 5% to 81%).[37] Such differences can be attributed to ethnicity or regional 132 
variation, inclusion and exclusion criteria, and no universal definition of AA-ONFH. Concerning the 133 
definition of AA-ONFH, although about 100 years have passed since the discovery of the association 134 
between alcohol abuse and ONFH, many recent studies did not pre-define the etiologic classification 135 
criteria of AA-ONFH.[4, 9, 10, 28-31, 38] Also, two thirds of our panelists did not answer their own 136 
criteria (Table 2). 137 
 The Delphi method is used as a consensus-building tool and was useful to deal with a such controversial 138 
issue.[39] Through the modified Delphi process, the panel determined the classification criteria for AA-139 
ONFH in the current study. This ARCO criteria requires determination of the dose of alcohol exposure 140 
before the classification of AA-ONFH. At-risk drinking is defined as >14 drinks/week for men or >7 141 
drinks/week for women by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).[40] Also, 142 
the World Health Organization (WHO) defines hazardous drinking as a regular average consumption of 143 
>40 to 60 grams/day for men or >20 to 40 grams/day for women.[41] Since 1 standard drink contains 144 
approximately 10 to 14 grams of pure ethanol, the amount at risk is estimated to be about 140 to 420 145 
grams/week for men or 70 to 280 grams/week for women according to the definitions of NIAAA or WHO. 146 
Concerning AA-ONFH, previous studies defined alcohol overuse as consumption of pure alcohol >400 147 
mL/week[42] or >400 mL/week for at least 6 months.[43] Since 1 mL of alcohol weighs 0.816 g and the 148 
amount of 400 mL pure alcohol is 326.4 g, the amount of pure ethanol (320 grams/week) in the current 149 
classification criteria is compatible or higher than in the NIAAA or WHO definition. Additionally, a 150 
recent meta-analysis showed that the odds ratio for AA-ONFH was 6.5 in case of average intake of 151 
alcohol 400 g/week.[44] Considering above findings, average drinking of pure ethanol 400 mL/week or 152 
more can be a risk factor for the development of AA-ONFH in both genders. The cut-off for the risk dose 153 
of pure alcohol is expressed as 400 mL/week using this criteria for convenience' sake. 154 
However, it is not easy to get the information about alcohol intake in all patients and the estimates of 155 
alcohol consumption could be biased due to limited human memory, a large time variation in drinking, 156 
diverse ethanol content and various categories of drink. The assessment methods for alcohol intake 157 
include the 7-day recall method, quantity frequency, and graduated quantity frequency.[45] Although the 158 
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7-day recall method, where patients report the quantity of alcohol intake on each day of the previous 159 
week, is widely used in epidemiological surveys,[46] it is beyond the scope of this study what is the most 160 
appropriate assessment tool to use our classification criteria for AA-ONFH. The dose of ethanol in a drink 161 
can be determined after obtaining information about its volume and ethanol concentration. Although 162 
ethanol conversion factors differ by country, alcohol contents are generally applied: for beer and light-163 
wine 5.0%, for wine 12%, and for spirits 40%. And the amount of pure alcohol (gm) is calculated to be 164 
Volume (mL) x Vol-% x 0.816 (g/ml) [47] For example, if he/she drinks 5 bottles (330 mL) of beer, 165 
ethanol consumption content is calculated as 330 mL/bottle × 5 bottles × 5% = 82.5 mL and ethanol 166 
amount is as 330 mL/bottle × 5 bottles × 5% × 0.816 g/mL = 67.32 gm. 167 
Drinking patterns as well as drinking amount can affect the development of AA-ONFH; regular drinkers 168 
were significantly associated with increased risk of AA-ONFH than occasional drinkers.[44, 48, 49] 169 
However, to date, no study has determined the risk period for ONFH development after beginning alcohol 170 
intake. It can be an issue of discrimination between AA-ONFH and other types of ONFH including 171 
idiopathic ONFH. In the current classification criteria, the panel included a minimal duration of alcohol 172 
exposure as a criterion (> 6 months).  173 
The natural history of ONFH has been well investigated. More than half of AA-ONFH patients have 174 
symptoms several months to years after development of the disease. Thus there is a time lag between the 175 
ONFH development and the diagnosis of the disease.[50] The diagnosis is often delayed because the 176 
diagnostic work-up is made only after the patient has pain andan MRI is not always used for the 177 
diagnosis.[51] unfortunately, we do not have any data on how long the effect of alcohol  remains. Thus, 178 
it is reasonable to include a certain period from the alcohol intake to the time of diagnosis in the criteria. 179 
When non-traumatic ONFH is diagnosed 1 year after abstinence from drinking, according to the ARCO 180 
criteria, he/she cannot be classified as AA-ONFH. 181 
 Other risk factors including glucocorticoid use and genetic predispositions can be a critical confounding 182 
factors when evaluating the effects of alcohol on the development of ONFH.[52, 53] However, it is 183 
difficult to evaluate the additive effects of other risk factors. The ARCO criteria have excluded patients 184 
who have other risk factor(s) other than excessive alcohol intake from AA-ONFH and exclusion criteria 185 
included a history of trauma, moderate- to high-dose glucocorticoid therapy, hereditary coagulopathies, 186 
Caisson disease, radiation therapy involving the femoral head, non-glucocorticoid chemotherapeutics for 187 
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cancer, sickle cell disease or Gaucher’s disease. 188 
 The current Delphi survey defined the classification criteria of AA-ONFH so that clinicians and 189 
researchers can objectively classify these patients. However, as described in the part I study of GA-190 
ONFH, the Delphi consensus method has limited validity in terms of scientific evidence and the iteration 191 
characteristics of the Delphi technique can potentially enable investigators to mold opinions. Also, 192 
because the classification criteria are not synonymous with diagnostic criteria, ARCO does recommend 193 
that the criteria should not be used as diagnostic criteria for AA-ONFH in clinical practice or as guidance 194 
in handling a legal issue. For research purposes, this classification criteria aims to have a high specificity 195 
(i.e., low false positivity) at the expense of a reduction of in sensitivity (i.e. increase in false negative 196 
results). The current classification criteria were established via expert consensus rather than quantitative 197 
analysis using patient data set. Therefore, the validity and reliability should be evaluated in a further study 198 
with large sample size. Through these ARCO classification criteria for AA-ONFH, more research data 199 
will be accumulated and our understanding will be increased. It is hoped that this work will be the 200 
impetus for the further development of diagnostic and treatment methods for this disease. 201 
Conclusion  202 
The current Delphi survey provides classification criteria for AA-ONFH. ARCO recommends using 203 
these criteria for studies about ONFH. 204 
Disclosure statement  The authors declare no conflict of interest. 205 
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the review of task force team. 375 
